These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16402511)

  • 1. ZD6474 headed for phase III trials in the fall.
    Oncology (Williston Park); 2005 Aug; 19(9):1140-2. PubMed ID: 16402511
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.
    Lee D
    Clin Lung Cancer; 2005 Sep; 7(2):89-91. PubMed ID: 16179094
    [No Abstract]   [Full Text] [Related]  

  • 3. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
    Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vandetanib for the treatment of non-small-cell lung cancer.
    Wong HL; de Boer RH
    Expert Opin Pharmacother; 2011 Oct; 12(14):2271-8. PubMed ID: 21819274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
    Matsumori Y; Yano S; Goto H; Nakataki E; Wedge SR; Ryan AJ; Sone S
    Oncol Res; 2006; 16(1):15-26. PubMed ID: 16783964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
    Ma W; Xu M; Liu Y; Liu H; Huang J; Zhu Y; Ji LJ; Qi X
    Int J Cancer; 2015 Jul; 137(2):409-19. PubMed ID: 25471638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two targets, one drug for new EGFR inhibitors.
    McNeil C
    J Natl Cancer Inst; 2006 Aug; 98(16):1102-3. PubMed ID: 16912259
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiangiogenic drugs in non-small cell lung cancer treatment.
    Cascone T; Troiani T; Morelli MP; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2006 Mar; 18(2):151-5. PubMed ID: 16462184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

  • 10. [Not Available].
    López-Brea M
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():1. PubMed ID: 27426240
    [No Abstract]   [Full Text] [Related]  

  • 11. ZD6474--clinical experience to date.
    Heymach JV
    Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S14-20. PubMed ID: 15928653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
    Rosen AC; Wu S; Damse A; Sherman E; Lacouture ME
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
    Williams KJ; Telfer BA; Brave S; Kendrew J; Whittaker L; Stratford IJ; Wedge SR
    Clin Cancer Res; 2004 Dec; 10(24):8587-93. PubMed ID: 15623642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies in lung cancer.
    Besse B; Ropert S; Soria JC
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix135-42. PubMed ID: 17631566
    [No Abstract]   [Full Text] [Related]  

  • 15. NSCLC drug targets acquire new visibility.
    Friedrich MJ
    J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
    [No Abstract]   [Full Text] [Related]  

  • 16. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.
    Natale RB
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S128-30. PubMed ID: 18520295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
    Hanrahan EO; Heymach JV
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4617-22. PubMed ID: 17671152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
    Normanno N; Di Maio M; Perrone F; Campiglio M
    J Clin Oncol; 2004 May; 22(10):2035-6; author reply 2036-7. PubMed ID: 15143103
    [No Abstract]   [Full Text] [Related]  

  • 19. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS; Hirsh V; Park K; Qin S; Blajman CR; Perng RP; Chen YM; Emerson L; Langmuir P; Manegold C
    J Clin Oncol; 2012 Apr; 30(10):1114-21. PubMed ID: 22370318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
    J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.